Тёмный
R3i Foundation
R3i Foundation
R3i Foundation
Подписаться
R3i - Residual Risk Reduction Initiative The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and microvascular complications in patients with atherogenic dyslipidemia, characterized by elevated triglycerides and low levels of high- density lipoprotein (HDL) cholesterol and unaddressed by current standards of care. Visit us at www.r3i.org/
What can we learn from the PROMINENT trial?
3:31
8 месяцев назад
Understanding NAFLD: novel molecular insights.
24:04
8 месяцев назад
Emerging target: PCSK7
22:00
Год назад
Inflammation in residual risk.
27:26
Год назад
Комментарии